Tdspharm KRX:464280KOSDAQ
티디에스팜 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days1
DART filings, 7 days0
Articles tracked1since Sep 11
In Q2 2026, Tdspharm reported revenue of ₩8.1bn, up 44.7% year on year, and operating profit of ₩1.0bn. Tdspharm (티디에스팜) appeared in 1 Korean news article and 0 DART filings over the past seven days. Coverage peaked on Sep 14 with 1 article. The most common catalyst was risk & warnings (1). It was most often mentioned alongside Yuyu Pharma.
Tdspharm quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩8.1bn | +44.7% | ₩1.0bn | ₩959m |
| Q1 2026 | ₩8.1bn | +52.9% | ₩1.3bn | ₩1.1bn |
| Q4 2025 derived | ₩8.7bn | +54.5% | ₩1.6bn | ₩1.6bn |
| Q3 2025 | ₩8.1bn | +25.0% | ₩1.6bn | ₩1.5bn |
| Q2 2025 | ₩5.6bn | -30.8% | ₩323m | ₩859m |
| Q1 2025 | ₩5.3bn | -28.3% | ₩189m | ₩366m |
| Q4 2024 derived | ₩5.6bn | -36.9% | ₩297m | ₩596m |
| Q3 2024 | ₩6.5bn | -0.6% | ₩847m | ₩847m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
Tdspharm top stories 2 weeks, by number of outlets
- 1
